Substance / Medication

Moxidectin

Overview

Active Ingredient
moxidectin
RxNorm CUI
1047072

Indications

Onchocerca volvulus [see Clinical Studies ( 14 )] Moxidectin Tablets are indicated for the treatment of onchocerciasis due toin adult and pediatric patients aged 4 years and older and weighing at least 13 kg. Limitations of Use: Onchocerca volvulus (O. volvulus) parasites Moxidectin Tablets does not kill adult. Follow-up evaluation is advised. O . volvulus The safety and efficacy of repeat administration of Moxidectin Tablets in patients withhas not been studied.

Labeler: Medicines Development for Global HealthUpdated: 2025-10-13T00:00:00.000ZFull label on DailyMed

Contraindications

When this intervention should not be used

None.

Indications & Related Conditions

Conditions associated via SNOMED clinical relationships

Administration & Protocol

Dosing, route, and treatment protocol

Detailed dosage and administration information is available in the full FDA drug label.

View full prescribing information on DailyMed

Monitoring & Follow-Up

Biomarkers relevant to this intervention via related conditions

No monitoring biomarkers have been mapped yet. Biomarker-intervention linkages are derived through related conditions and will expand as the knowledge graph grows.

Clinical Trials

2 trials linked to this intervention

2
Total Trials
1
Recruiting
0
With Results

Research Evidence

Published studies and systematic reviews

Sort:
Ivermectinmoxidectin for treatinginfection: a systematic review.
Henriquez-Camacho Cesar, Pérez-Molina Jose A, Buonfrate Dora et al. · Parasitology · 2024
PMID: 39819639Meta-AnalysisFull text (PMC)
A systematic review of moxidectin as a treatment for parasitic infections in mammalian species.
Schraven Andrea L, Stannard Hayley J, Old Julie M · Parasitol Res · 2021
PMID: 33615411Meta-Analysis
Moxidectin combination therapies for lymphatic filariasis: an open-label, observer-masked, randomised controlled trial.
Koudou Guibehi Benjamin, Bjerum Catherine M, Ouattara Foungoye Allassane et al. · Lancet Infect Dis · 2025
PMID: 40345209RCT
Pharmacokinetics of oral moxidectin in individuals with Onchocerca volvulus infection.
Tan Beesan, Opoku Nicholas, Attah Simon K et al. · PLoS Negl Trop Dis · 2022
PMID: 35333880RCTFull text (PMC)

Research data from MEDLINE/PubMed

Benefits & Expected Outcomes

Benefits, expected outcomes, efficacy data, and NNT (Number Needed to Treat) are pending physician authorship and evidence review.

Risks & Side Effects

Adverse reaction and safety data for this drug is sourced from the FDA-approved label.

View adverse reactions & drug interactions on DailyMed

Related Symptoms

Symptoms associated with conditions this intervention addresses

No related symptoms have been mapped yet. Symptom linkages are derived through associated conditions.

Alternatives & Comparisons

Alternative treatments, comparison data, and clinical decision support are pending physician authorship.

Medical Disclaimer

This information is for educational purposes only and does not constitute medical advice, diagnosis, or treatment. Always consult with a qualified healthcare provider regarding any medical condition or treatment plan.

Do not start, stop, or change any treatment without consulting your healthcare provider.

Quick Facts

Type
Substance / Medication
Fully Specified Name
Moxidectin (substance)
SNOMED CT
781257003
UMLS CUI
C0163557
RxNorm CUI
1047072
Labeler
Medicines Development for Global Health

Clinical Data

This intervention maps to 1 entities in the Ltrl knowledge graph.

1
Conditions
0
Biomarkers
0
Specialists
0
Symptoms
2
Clinical Trials

Data is sourced from SNOMED CT, UMLS, and the Ltrl clinical knowledge graph. Content sections marked as pending require physician authorship. Consult a healthcare provider before starting any treatment.